Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis
- PMID: 10074517
- PMCID: PMC88640
- DOI: 10.1128/JCM.37.4.1004-1007.1999
Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis
Abstract
Burkholderia cepacia selective agar (BCSA) has previously been devised for isolation of B. cepacia from respiratory secretions of patients with cystic fibrosis and tested under research laboratory conditions. Here we describe a study in which BCSA, oxidation-fermentation polymyxin bacitracin lactose agar (OFPBL), and Pseudomonas cepacia agar (PCA) were compared in routine culture procedures for the ability to grow B. cepacia and inhibit other organisms. Three hundred twenty-eight specimens from 209 patients at two pediatric centers and 328 specimens from 109 adults were tested. Plates were inoculated, incubated, and read for quality and quantity of growth at 24, 48, and 72 h. Five (1.5%) specimens from 4 (1.9%) children and 75 (22.9%) specimens from 16 (14.7%) adults grew B. cepacia complex. At 24, 48, and 72 h, BCSA achieved 43, 93, and 100% detection, respectively; OFPBL achieved 26, 84, and 96%, respectively; and PCA achieved 33, 74, and 84% detection, respectively. Quality was assessed as pinpoint or good growth. At 24 h, most cultures growing B. cepacia complex had pinpoint colonies. By 48 and 72 h, 48 and 69% of B. cepacia complex cultures, respectively, had good growth on BCSA, while on OFPBL 19 and 30%, respectively, had good growth and on PCA 11 and 18%, respectively, had good growth. BCSA was superior to OFPBL and PCA in suppressing organisms other than B. cepacia complex; 40 non-B. cepacia complex organisms were isolated from BCSA, 263 were isolated from OFPBL, and 116 were isolated from PCA. We conclude that BCSA is superior to OFPBL and PCA in its ability to support the growth of B. cepacia complex and to suppress other respiratory organisms.
Figures

Similar articles
-
Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium.J Clin Microbiol. 1997 Mar;35(3):614-9. doi: 10.1128/jcm.35.3.614-619.1997. J Clin Microbiol. 1997. PMID: 9041399 Free PMC article.
-
Improved cultural detection of Burkholderia cepacia from sputum in patients with cystic fibrosis.J Clin Pathol. 2001 Oct;54(10):803-5. doi: 10.1136/jcp.54.10.803. J Clin Pathol. 2001. PMID: 11577134 Free PMC article.
-
Comparison of two selective media developed to isolate Pseudomonas cepacia from patients with cystic fibrosis.Diagn Microbiol Infect Dis. 1987 Apr;6(4):277-82. doi: 10.1016/0732-8893(87)90175-1. Diagn Microbiol Infect Dis. 1987. PMID: 3581734
-
[An opportunistic pathogen frequently isolated from immunocompromised patients: Burkholderia cepacia complex].Mikrobiyol Bul. 2012 Apr;46(2):304-18. Mikrobiyol Bul. 2012. PMID: 22639321 Review. Turkish.
-
Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis?Transpl Infect Dis. 2001 Sep;3(3):149-60. doi: 10.1034/j.1399-3062.2001.003003149.x. Transpl Infect Dis. 2001. PMID: 11493397 Review.
Cited by
-
Comparative evaluation of the BD Phoenix and VITEK 2 automated instruments for identification of isolates of the Burkholderia cepacia complex.J Clin Microbiol. 2002 May;40(5):1743-8. doi: 10.1128/JCM.40.5.1743-1748.2002. J Clin Microbiol. 2002. PMID: 11980954 Free PMC article.
-
Adaptation and Survival of Burkholderia cepacia and B. contaminans During Long-Term Incubation in Saline Solutions Containing Benzalkonium Chloride.Front Bioeng Biotechnol. 2020 Jun 26;8:630. doi: 10.3389/fbioe.2020.00630. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32714902 Free PMC article.
-
Distinguishing species of the Burkholderia cepacia complex and Burkholderia gladioli by automated ribotyping.J Clin Microbiol. 2000 May;38(5):1876-84. doi: 10.1128/JCM.38.5.1876-1884.2000. J Clin Microbiol. 2000. PMID: 10790116 Free PMC article.
-
A selective genome-guided method for environmental Burkholderia isolation.J Ind Microbiol Biotechnol. 2019 Mar;46(3-4):345-362. doi: 10.1007/s10295-018-02121-x. Epub 2019 Jan 24. J Ind Microbiol Biotechnol. 2019. PMID: 30680473
-
Infections in patients with cystic fibrosis: diagnostic microbiology update.Clin Lab Med. 2014 Jun;34(2):197-217. doi: 10.1016/j.cll.2014.02.001. Epub 2014 Apr 12. Clin Lab Med. 2014. PMID: 24856524 Free PMC article. Review.
References
-
- Burdge D R, Noble M A, Campbell M E, Krell V L, Speert D P. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis. 1994;20:445–448. - PubMed
-
- Burns J L, Emerson J, Stapp J R, Yim D L, Krzewsinski J, Louden L, Ramsey B W, Clausen C R. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis. 1998;27:158–163. - PubMed
-
- Coenye T, Govan J R W, Kersters K, Vandamme P. Proceedings of the 12th North American Cystic Fibrosis Conference. 1998. Automated AFLP analysis for the identification of Burkholderia species and genomovars occurring in CF patients, abstr. 428.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical